← Back to Search

Bcl-2 inhibitor

AMG 427 for Acute Myeloid Leukemia (20170528 Trial)

Phase 1
Waitlist Available
Research Sponsored by Amgen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 months
Awards & highlights

Summary

This trial tests AMG 427, a new drug, in adults with a specific type of blood cancer. It aims to find the safest and most effective amount of the drug by adjusting the dosage over time.

Eligible Conditions
  • Relapsed/Refractory Acute Myeloid Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of subjects who experience a dose limiting toxicity (DLT)
Subject incidence of treatment-emergent adverse events (TEAEs)
Subject incidence of treatment-related adverse events (TRAEs)

Trial Design

2Treatment groups
Experimental Treatment
Group I: Dose Expansion PhaseExperimental Treatment1 Intervention
AMG 427 MTD identified in dose escalation phase (or lower) will be administered to subjects.
Group II: Dose Escalation PhaseExperimental Treatment1 Intervention
AMG 427 Dose-finding phase of the study

Find a Location

Who is running the clinical trial?

AmgenLead Sponsor
1,420 Previous Clinical Trials
1,382,886 Total Patients Enrolled
MDStudy DirectorAmgen
961 Previous Clinical Trials
928,801 Total Patients Enrolled
~9 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top